 FSD Pharma CSE:HUGE, NASDAQ:HUGE Inc has announced that it has submitted Investigation New Drug applications to the US Food and Drug Administration FDA and Health Canada for its planned Phase 2 clinical trial of FSD-201 for the treatment of a yet-to-be-disclosed inflammatory disorder. The biotech noted that FSD-201, its proprietary formulation of ultra micronized palmitoylethanolamide, or ultramicronized PEA, was shown to be safe and well tolerated during a Phase 1 clinical trial. 